123 related articles for article (PubMed ID: 29667616)
1. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.
Haj-Mirzaian A; Burk KS; Lacson R; Glazer DI; Saini S; Kibel AS; Khorasani R
JAMA Netw Open; 2024 Mar; 7(3):e244258. PubMed ID: 38551559
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.
Wang S; Kozarek J; Russell R; Drescher M; Khan A; Kundra V; Barry KH; Naslund M; Siddiqui MM
Eur Urol Oncol; 2024 Apr; 7(2):189-203. PubMed ID: 37640584
[TBL] [Abstract][Full Text] [Related]
4. PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml.
Wen J; Liu W; Shen X; Hu W
Sci Rep; 2024 Mar; 14(1):6570. PubMed ID: 38503972
[TBL] [Abstract][Full Text] [Related]
5. Risk factor analysis and optimal cutoff value selection of PSAD for diagnosing clinically significant prostate cancer in patients with negative mpMRI: results from a high-volume center in Southeast China.
Lin S; Jiang W; Ding J; Hao S; Chen H; Xie L; Zheng X
World J Surg Oncol; 2024 May; 22(1):140. PubMed ID: 38802859
[TBL] [Abstract][Full Text] [Related]
6. Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision.
Guo S; Zhang J; Wang Y; Jiao J; Li Z; Cui C; Chen J; Yang W; Ma S; Wu P; Jing Y; Wen W; Kang F; Wang J; Qin W
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):288-293. PubMed ID: 38160227
[TBL] [Abstract][Full Text] [Related]
7. Deep learning model for the detection of prostate cancer and classification of clinically significant disease using multiparametric MRI in comparison to PI-RADs score.
Yang C; Li B; Luan Y; Wang S; Bian Y; Zhang J; Wang Z; Liu B; Chen X; Hacker M; Li Z; Li X; Wang Z
Urol Oncol; 2024 May; 42(5):158.e17-158.e27. PubMed ID: 38388243
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Utility of PI-RADS 2.1, ADC Values, and Combined Use of Both, for the Diagnosis of Transition Zone Prostate Cancers.
Liu X; Xiong Q; Zeng W; Yang R; Wen Y; Li X
J Comput Assist Tomogr; 2024 Mar-Apr 01; 48(2):206-211. PubMed ID: 38149651
[TBL] [Abstract][Full Text] [Related]
9. The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score.
Baudewyns A; Guenzel K; Halinski A; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Jabbour T; Bourgeno HA; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Zahr RA; Ploussard G; Fiard G; Rysankova K; Bui AP; Taha F; Windisch O; Benamran D; Vlahopoulos L; Assenmacher G; Roumeguère T; Peltier A; Diamand R
World J Urol; 2024 May; 42(1):322. PubMed ID: 38747982
[TBL] [Abstract][Full Text] [Related]
10. Radiomics from multisite MRI and clinical data to predict clinically significant prostate cancer.
Krauss W; Frey J; Heydorn Lagerlöf J; Lidén M; Thunberg P
Acta Radiol; 2024 Mar; 65(3):307-317. PubMed ID: 38115809
[TBL] [Abstract][Full Text] [Related]
11. Risk-Adapted Strategy Combining Magnetic Resonance Imaging and Prostate-Specific Antigen Density to Individualize Biopsy Decision in Patients With PI-RADS 3 ``Gray Zone'' Lesions.
Akpinar C; Oz DK; Oktar A; Suer E; Ozden E; Haliloglu N; Gulpinar O; Gokce MI; Gogus C; Baltaci S
Clin Genitourin Cancer; 2024 Mar; 22(3):102071. PubMed ID: 38555682
[TBL] [Abstract][Full Text] [Related]
12. PSA-density, DRE, and PI-RADS 5: potential surrogates for omitting biopsy?
Falkenbach F; Ambrosini F; Kachanov M; Ortner G; Maurer T; Köhler D; Beyersdorff D; Graefen M; Budäus L
World J Urol; 2024 Mar; 42(1):182. PubMed ID: 38506941
[TBL] [Abstract][Full Text] [Related]
13. Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
Dong Q; Wang C; Shen D; Ma Y; Zhang B; Xu S; Tao T; Xiao J
Prostate; 2024 Jun; 84(8):780-787. PubMed ID: 38558415
[TBL] [Abstract][Full Text] [Related]
14. PI-RADS v2.1 evaluation of prostate "nodule in nodule" variants: clinical, imaging, and pathological features.
Sun M; Xu L; Zhang X; Cao L; Chen W; Liu K; Wu H; Xie D
Insights Imaging; 2024 Mar; 15(1):79. PubMed ID: 38499703
[TBL] [Abstract][Full Text] [Related]
15. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
Emmett L; Papa N; Hope TA; Fendler W; Calais J; Burger I; Eiber M; Barbato F; Moon D; Counter W; John N; Xue A; Franklin A; Thompson J; Rasiah K; Frydenberg M; Yaxley J; Buteau J; Agrawal S; Ho B; Nguyen A; Liu V; Lee J; Woo H; Hsiao E; Sutherland T; Perry E; Stricker P; Hofman MS; Kasivisvanathan V; Roberts M; Murphy D
J Urol; 2024 May; ():101097JU0000000000004010. PubMed ID: 38758680
[TBL] [Abstract][Full Text] [Related]
16. Using IsoPSA With Prostate Imaging Reporting and Data System Score May Help Refine Biopsy Decision Making in Patients With Elevated PSA.
Benidir T; Lone Z; Wood A; Abdallah N; Campbell R; Bajic P; Purysko A; Nguyen JK; Kaouk J; Haber GP; Eltemamy M; Stein R; Haywood S; Klein EA; Almassi N; Campbell SC; Abouassaly R; Weight CJ
Urology; 2023 Jun; 176():115-120. PubMed ID: 36965817
[TBL] [Abstract][Full Text] [Related]
17. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Rajwa P; Mori K; Huebner NA; Martin DT; Sprenkle PC; Weinreb JC; Ploussard G; Pradere B; Shariat SF; Leapman MS
J Urol; 2021 Sep; 206(3):507-516. PubMed ID: 33904755
[TBL] [Abstract][Full Text] [Related]
18. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis.
Fazekas T; Shim SR; Basile G; Baboudjian M; Kói T; Przydacz M; Abufaraj M; Ploussard G; Kasivisvanathan V; Rivas JG; Gandaglia G; Szarvas T; Schoots IG; van den Bergh RCN; Leapman MS; Nyirády P; Shariat SF; Rajwa P
JAMA Oncol; 2024 Apr; ():. PubMed ID: 38576242
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
Rajendran I; Lee KL; Thavaraja L; Barrett T
Br J Radiol; 2024 Jan; 97(1153):113-119. PubMed ID: 38263825
[TBL] [Abstract][Full Text] [Related]
20. Nomograms for predicting clinically significant prostate cancer in men with PI-RADS-3 biparametric magnetic resonance imaging.
Liang Z; Feng T; Zhou Y; Yang Y; Sun Y; Zhou Z; Yan W; Cao F
Am J Cancer Res; 2024; 14(1):73-85. PubMed ID: 38323293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
